Findings

What do systematic reviews say?

6 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 57.1%Moderate 3 · 42.9%High 0 · 0%

Mycophenolate sodium + oral steroids vs oral steroids alone

Complete remission · minimal change disease in adults with nephrotic syndrome

Mycophenolate sodium + oral steroids showed no clear difference in complete remission Time frame: 4 weeks compared with oral steroids alone (moderate certainty).

2 findings from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 1.12 [0.84, 1.5]
1 study · 114 participants
Moderate
Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 1.08 [0.84, 1.38]
2 studies · 134 participants
Moderate

Mycophenolate sodium + oral steroids vs oral steroids alone

Complete or partial remission · minimal change disease in adults with nephrotic syndrome

Mycophenolate sodium + oral steroids showed no clear difference in complete or partial remission Time frame: 24 weeks to end of treatment compared with oral steroids alone (moderate certainty).

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 0.92 [0.75, 1.12]
2 studies · 134 participants
Moderate

Mycophenolate sodium + oral steroids vs oral steroids alone

Relapse · minimal change disease in adults with nephrotic syndrome

Mycophenolate sodium + oral steroids showed no clear difference in relapse Time frame: 24 weeks compared with oral steroids alone (low certainty).

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 0.43 [0.08, 2.25]
2 studies · 80 participants
Low

Mycophenolate sodium + oral steroids vs oral steroids alone

Adverse events: death · minimal change disease in adults with nephrotic syndrome

Mycophenolate sodium + oral steroids showed no clear difference in adverse events: death compared with oral steroids alone (low certainty).

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 0.67 [0.12, 3.84]
1 study · 116 participants
Low

Mycophenolate sodium + oral steroids vs oral steroids alone

Acute kidney injury · minimal change disease in adults with nephrotic syndrome

Mycophenolate sodium + oral steroids showed no clear difference in adverse events: acute kidney injury compared with oral steroids alone (low certainty).

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 0.5 [0.05, 5.36]
1 study · 116 participants
Low

Mycophenolate sodium + oral steroids vs oral steroids alone

Adverse events: new‐onset glucose intolerance · minimal change disease in adults with nephrotic syndrome

Mycophenolate sodium + oral steroids showed no clear difference in adverse events: new‐onset glucose intolerance compared with oral steroids alone (low certainty).

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 0.2 [0.01, 4.08]
2 studies · 136 participants
Low